Immune system
A food-safe antibiotic peptide used as a preservative for over 50 years — it kills tough bacteria like MRSA and Listeria by two mechanisms at once.
Start here
Nisin is an antimicrobial peptide made by Lactococcus lactis, a harmless bacterium used in dairy fermentation. It has served for decades as a natural food preservative — the FDA affirmed it as GRAS ('generally recognized as safe') in 1988 7 — for example to stop Clostridium botulinum in pasteurized cheese spreads. It kills harmful bacteria in two ways at once: blocking construction of their cell walls and punching holes in their membranes. It is not an approved drug; medical uses such as wound care are still investigational.
Nisin is a lantibiotic (modified antimicrobial peptide) produced by beneficial bacteria that kills harmful bacteria by disrupting cell membranes and is widely used as a natural food preservative.
Nisin is a 34-amino acid lantibiotic (a germ-killing peptide made by bacteria) produced by Lactococcus lactis. It contains chemically modified amino acids, including lanthionine, methyl-lanthionine, and unusual ring structures (A, B, C, D, E rings). These changes create a rigid structure that enzymes struggle to break down, which allows oral bioavailability (it can work when swallowed). Nisin kills bacteria in two ways: (1) it forms nisin-lipid II complexes on bacterial cell membranes, blocking peptidoglycan synthesis (the building of the bacterial cell wall); and (2) it makes direct holes in the membrane (pore formation). This two-part attack makes it hard for bacteria to become resistant, compared with antibiotics that hit a single target, which makes nisin especially valuable as a food-grade germ-killer and an anti-biofilm agent (it breaks up the slimy layers bacteria form).
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 7 sources at the bottom.
Immune
Nisin provides potent antimicrobial activity through its unique dual mechanism: binding lipid II blocks cell wall synthesis (like vancomycin) while simultaneously using the lipid II-nisin complex to form 2 nm transmembrane pores for rapid bacterial lysis — this two-pronged killing mechanism at MIC 0.5-4 μg/mL makes resistance development extremely difficult and has maintained efficacy across 50+ years of use
Healing & Recovery
Emerging topical wound care applications exploit nisin's potent anti-gram-positive and anti-biofilm activity, with lanthionine-stabilized structure providing protease resistance in wound environments — veterinary mastitis treatment demonstrates clinical antimicrobial efficacy, supporting translation to human wound care
Anti-Aging
Potential anticancer activity (IC50 11.68 μg/mL against MCF-7 breast cancer cells) through selective membrane disruption of cancer cells, combined with immunomodulatory properties and the safety profile of 50+ years of human dietary consumption, positions nisin as an emerging geroprotective research compound
The most-asked question
The research-reported range is 10–50 mcg/mL, once daily.
Wound antimicrobial research, Topical infection control
10-50 mcg/mL applied to the affected area
Topical antimicrobial concentration range used in wound-care and infection-control research 5. Investigational; not an approved human therapeutic route.
The ceiling: 25 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Nisin:
Nisin comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Nisin exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Nisin's recorded schedule.
Timing
Take Nisin at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Nisin can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Nisin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
At FDA GRAS concentrations used in food preservation (ADI 0.13 mg/kg BW), nisin has no documented side effects across 50+ years of global dietary consumption by millions of people.
What to do No management needed. Nisin at dietary levels is one of the most well-documented safe food additives in history.
At oral doses significantly exceeding normal dietary exposure in research settings, mild gastrointestinal discomfort (nausea, mild cramping) may occur.
What to do Take with food. Reduce dose if symptoms persist. GI effects are typically transient and dose-dependent.
Mild local irritation, redness, or warmth at topical application sites in wound care or dental research settings.
What to do Generally self-limiting. Reduce concentration if irritation is excessive. Nisin is most stable and active at acidic pH, which may contribute to local irritation.
Worth knowing about, but most people never see these.
Allergic reaction in individuals with milk protein sensitivity. While purified nisin is a peptide from Lactococcus lactis (not a milk protein), commercial preparations may contain trace dairy-associated contaminants.
What to do Screen for milk protein allergy before use. Use highly purified pharmaceutical-grade nisin for sensitive individuals. Discontinue if allergic symptoms occur.
Selective gram-positive killing without gram-negative coverage could theoretically shift wound or oral microbiome toward gram-negative dominance in extended topical use.
What to do Monitor for gram-negative overgrowth in prolonged topical research applications. Consider combination with EDTA or polymyxin for broad-spectrum coverage.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse effects documented across 50+ years of global food use. Oral LD50 in mice is 174 mg/kg, comparable to table salt (3,000 mg/kg for NaCl). The therapeutic index for antimicrobial activity is extraordinarily wide.
What to do Continue monitoring in novel therapeutic applications. The extensive food safety record provides strong reassurance, though clinical trial data for non-food therapeutic uses is still developing.
Week by week
Is it right for you?
Nisin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Nisin. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Nisin is particularly well-suited for individuals focused on food preservation as a natural antimicrobial alternative to chemical preservatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nisin is particularly well-suited for individuals focused on research into novel antimicrobial therapeutics based on lantibiotic scaffolds. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nisin is particularly well-suited for individuals focused on anti-listeria and anti-clostridium strategies in food safety and clinical settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nisin is particularly well-suited for individuals focused on development of antimicrobial wound dressings and dental applications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nisin holds FDA GRAS status since 1988 with over 50 years of documented safe human consumption, making it the only antimicrobial peptide with this comprehensive long-term safety record. Oral LD50 of 174 mg/kg in mice (comparable to table salt) demonstrates extraordinary safety margin. Acceptable daily intake established at 0.13 mg/kg body weight with no reported serious adverse events at this or higher levels. Primary risk is milk protein contamination during production, requiring screening for lactose-intolerant or milk-allergic individuals.
FDA GRAS designation based on 50+ years of food-industry safety data with millions of exposed consumers globally. Bacterial production method prevents synthetic impurities; stability through pasteurization and food processing verified via microbiological and mass spectrometry analysis. Animal toxicity studies and human safety monitoring across multiple continents show no systemic (affecting the whole body) toxicity, genotoxicity, or carcinogenic potential. European Food Safety Authority also designated as safe food additive (E234).
Keeping it good
Store Nisin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Nisin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2016
Nisin binds to bacterial lipid II (a building block bacteria use for their cell walls) through its pyrophosphate group (a small chemical part), and it needs the complete sugar unit for tight binding and for forming pores (tiny holes) in bacterial membranes.
't Hart P, Oppedijk SF, Breukink E, et al.
2017
Research (2016) on nisin contributes important scientific knowledge about its biological and pharmacological properties.
Ahmadi S, Ghollasi M, Hosseini HM
2026
PLoS One 2026;21(6):e0352312 (PMID 42335141). Nisin was toxic to MCF-7 and MDA-MB-231 breast cancer cells (IC50 5-8 µM, the amount that kills half the cells) with lower toxicity to normal cells. It made membranes leaky mainly by acting on anionic lipids (negatively charged fats in cell membranes), and worked together with doxorubicin (a cancer drug) to increase apoptosis (programmed cell death).
Phetdee C, Naephrai S, Pradain M, Panporm Y, Ahmad U, Prangkio P
2025
Study (2014) elucidates the molecular mechanism of action and biological pathways by which nisin produces therapeutic effects.
Al-Khazaleh AK, Alsherbiny MA, Chang D, et al.
2021
Lab-dish study of nisin (as a nisin-biogel, a gel containing nisin) against Staphylococcus aureus bacteria taken from diabetic foot wound infections. The mean nisin MIC (the lowest amount that stops bacterial growth) against these wound samples was approximately 22.5 ug/mL, and lower amounts (~2.8-11.25 ug/mL) were tested for effects on virulence-gene expression (how much the genes that make the bacteria harmful are switched on). This supports the ~10-50 ug/mL range used in skin and wound germ-fighting formulation work; it is lab-dish and formulation research, not an approved human therapeutic dose.
Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M
2023
An MTT assay (a lab test of cell survival) reports that nisin is highly and selectively toxic to the MCF-7 breast cancer cell line, with an IC50 (the amount that kills half the cells) of 11.68 µg/ml (PMID 37807320). This is the source of the page's MCF-7 IC50 figure.
Said Taha S, Abdulrahman ZFA, Othman RT (2023)
1988
Nisin preparation from Streptococcus lactis fermentation is affirmed as GRAS (generally recognized as safe; 53 FR 11250, 6 April 1988) for use as an antimicrobial to stop Clostridium botulinum spores from growing and making toxin in pasteurized cheese spreads and process cheese spreads, at levels not exceeding good manufacturing practice. This is a food-ingredient status, not drug approval.
U.S. Food and Drug Administration (Electronic Code of Federal Regulations)
If this isn't the right fit
Your questions
Nisin is a 34-amino acid antimicrobial peptide produced by the bacterium Lactococcus lactis. It is called a 'lantibiotic' (lanthionine-containing antibiotic) because it contains unusual amino acids — lanthionine and methyl-lanthionine — that are created by post-translational modification of the ribosomal peptide. These unusual amino acids form five thioether ring bridges (rings A-E) that give nisin its characteristic polycyclic structure, exceptional stability against heat and proteases, and its unique ability to bind lipid II. First discovered in 1928 by Rogers and Whittier at the USDA, nisin was named in 1947 and has been used in food preservation for over 50 years.
Nisin kills bacteria through two simultaneous mechanisms. First, its N-terminal lanthionine rings (A and B) bind with high affinity to lipid II, the essential membrane-anchored precursor for cell wall synthesis. This alone blocks peptidoglycan construction, similar to vancomycin. Second, the bound lipid II-nisin complex then serves as a docking molecule — nisin's C-terminal region inserts into the membrane using lipid II as an anchor, forming 2 nm pores made of approximately 8 nisin and 4 lipid II molecules. These pores cause rapid ion leakage, ATP loss, and membrane depolarization. This dual pathway means bacteria would need to simultaneously develop resistance to both mechanisms — explaining why significant resistance has not emerged despite 50+ years of use.
Nisin has one of the strongest safety records of any antimicrobial agent. It received FDA GRAS (Generally Recognized As Safe) status in 1988 and is approved as food additive E234 in over 50 countries. The Joint FAO/WHO Expert Committee established an ADI (Acceptable Daily Intake) of 0.13 mg/kg body weight. The oral LD50 in mice is 174 mg/kg — comparable to table salt. Importantly, nisin is rapidly degraded by digestive enzymes (pancreatic proteases) in the human GI tract, meaning it does not accumulate or affect the normal gut microbiome at dietary levels. No adverse effects have been documented across decades of global food use.
Gram-negative bacteria have an additional outer membrane that gram-positive bacteria lack. This outer membrane acts as a physical barrier preventing nisin from reaching its target — lipid II in the cytoplasmic membrane. However, this limitation can be overcome by combining nisin with outer membrane-disrupting agents: EDTA chelates divalent cations that stabilize the outer membrane, and polymyxin directly disrupts the outer membrane lipid structure. Both combinations effectively extend nisin's activity to gram-negative pathogens including E. coli and Pseudomonas.
While nisin is currently approved only for food preservation, there is growing research interest in therapeutic applications. It has shown efficacy in veterinary mastitis treatment (intramammary infusion), topical wound care research, dental applications (anti-plaque, anti-periodontal disease), and even anticancer research (selective cytotoxicity against cancer cells). Its extraordinary safety profile from 50+ years of dietary use provides a strong foundation for clinical development. However, formal human clinical trials for therapeutic indications are still in early stages, and nisin is not currently approved for clinical antimicrobial use.
Both nisin and vancomycin target lipid II, a building block bacteria need for their cell wall, but they work differently. Vancomycin binds the end of lipid II's peptide chain (D-Ala-D-Ala), blocking wall construction. Nisin binds the pyrophosphate region (the linking phosphate group) of lipid II using its lanthionine rings (special ring-shaped bridges in its structure), and then also punches pores in the bacterial membrane — a second killing mechanism that vancomycin lacks. This dual action makes nisin effective against some vancomycin-resistant bacteria. However, vancomycin is established for body-wide IV therapy, while nisin's clinical use is limited to food preservation and topical research applications because it is a peptide and its absorption and clearance in the body (pharmacokinetics (how the body absorbs and clears a compound)) are limited.
7 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Nisin research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek